The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Schedule 1 - Original Invest

6 Oct 2006 16:28

AIM06 October 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME: ORIGINAL INVESTMENTS PLC (TO BE RENAMED VIALOGY PLC ON ADMISSION) COMPANY ADDRESS: ASHCOME COURTWOOLSACK WAYGODALMINGSURREY COMPANY POSTCODE: GU7 1LQ COUNTRY OF INCORPORATION: UK COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES: ViaLogy was founded in 1999 by a group of senior scientists and managers in supercomputing and ultra-computingtechnologies at the Caltech/NASA Jet Propulsion Laboratory (JPL) in Pasadena, California. Leveraging their priorexpertise and work at JPL in remote sensing and signal processing, ViaLogy scientists developed a technology toseparate the background 'noise' that envelops weak signals called Quantum Resonance Interferometry (QRI), which has thepotential to be adapted to a wide range of measurement, instrumentation and other applications. The initial test results on QRI, undertaken in the microarray industry, indicated that the technology was able todetect and discriminate signals with an intensity 1,000 times lower than RMS (root mean square) background noise. Thetechnology was the subject of further development work undertaken in the mass spectrometry industry. Other developmentactivities were carried out in the areas of sensor data processing and transference. The board and management team of ViaLogy consider that the technology is sufficiently advanced to be of considerablebenefit in a number of industrial areas and a planned programme of commercialisation has commenced. Discussions at bothdevelopment and commercial levels are being held with a number of international companies and national authorities toverify the suitability of incorporating the ViaLogy technology into existing and/or new products. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to which itseeks admission and the number and type to be held as treasury shares): 403,256,437 ORDINARY SHARES OF 1P EACH CAPITAL TO BE RAISED ON ADMISSION: NIL FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS: DIRECTORS: JAMES DERRICK SLATER, CHAIRMAN (TO RESIGN ON ADMISSION) TERENCE BOND, MANAGING DIRECTOR AND DEPUTY CHAIRMAN (TO BECOME EXECUTIVE CHAIRMAN ON ADMISSION) DR RICHARD PETER DIXEY, NON EXECUTIVE DIRECTOR (TO RESIGN ON ADMISSION) JULIAN GEORGE VIGGARS, NON EXECUTIVE DIRECTOR (TO RESIGN ON ADMISSION) PROPOSED DIRECTORS: MICHAEL WOODS KELLY, PROPOSED CHIEF EXECUTIVE OFFICER DR. SANDEEP GULATI, PROPOSED CHIEF TECHNICAL OFFICER GEORGE REHM, PROPOSED NON-EXECUTIVE DIRECTOR DR. ROBERT WILLIAM DEAN, PROPOSED NON-EXECUTIVE DIRECTOR PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION: Existing Following AdmissionDirector Number of Percentage of Number of Percentage of Ordinary Shares issued ordinary Ordinary Shares issued ordinary share capital (%) share capital (%) James Derrick Slater 26,485,000 8.5 26,485,000 6.6Terence Bond 13,925,000 4.5 13,925,000 3.5Christopher Slater 12,585,000 4.0 12,585,000 3.1Atlas Capital S.A. 17,700,000 5.7 17,700,000 4.4Dr. John Broome 12,500,000 5.3 13,316,542 3.3Aeris Holdings AG Nil Nil 60,883,923 15.1 NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: NONE ANTICIPATED ACCOUNTING REFERENCE DATE: 31 MARCH EXPECTED ADMISSION DATE: 30 OCTOBER 2006 NAME AND ADDRESS OF NOMINATED ADVISER: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL NAME AND ADDRESS OF BROKER: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THISWILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL THE ADMISSION DOCUMENT CONTAINS FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES. DATE OF NOTIFICATION: 6 OCTOBER 2006 NEW/ UPDATE (see note): NEW This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.